

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:10:28 ON 10 APR 2003)

FILE 'REGISTRY' ENTERED AT 14:10:36 ON 10 APR 2003

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 75 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:12:00 ON 10 APR 2003

=> s l3

L4 2 L3

=> d bib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 2001:185718 CAPLUS

DN 134:237481

TI Preparation of 4-[4-[2-(2-pyridyl- or 5,6,7,8-tetrahydro-1,8-naphthyridin-
2-yl)ethoxy]phenyl]butanoic acid derivatives as vitronectin receptor
antagonists

IN Manley, Peter J.; Miller, William H.; Uzinskas, Irene N.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

applicant's own

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017959	A2	20010315	WO 2000-US24514	20000907
	WO 2001017959	A3	20010510		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000073543	A5	20010410	AU 2000-73543	20000907
	EP 1218005	A2	20020703	EP 2000-961619	20000907
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003508516	T2	20030304	JP 2001-521706	20000907
	NO 2002001113	A	20020503	NO 2002-1113	20020306
PRAI	US 1999-152780P	P	19990907		
	WO 2000-US24514	W	20000907		
OS	MARPAT 134:237481				
GI					



chain nodes :
 7 8 9 10 11 12 13 14 16 18 19 20
 ring nodes :
 1 2 3 4 5 6
 chain bonds :
 3-7 7-20 8-9 9-10 9-16 10-11 11-12 11-13 13-14 18-19 19-20
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 3-7 7-20 9-16 11-12 11-13 13-14 18-19
 exact bonds :
 8-9 9-10 10-11 19-20
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :


G1:H,Ak

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom 17:CLASS 18:Atom 19:CLASS 20:CLASS

=> d scan

L3 75 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-
pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI)
MF C25 H29 N3 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 75 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Thiazolepropanoic acid, 5-methyl-.beta.-[[4-[2-[6-(methylamino)-2-
pyridinyl]ethoxy]phenyl]methyl]- (9CI)
MF C22 H25 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.55

148.76




FILE 'CAPLUS' ENTERED AT 14:12:00 ON 10 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December




AB The title compds. (I; R1 = heterocyclcyl, aryl; R2 = Q, Q1) or pharmaceutically acceptable salts thereof, which are vitronectin (.alpha.V.beta.3) receptor antagonists, are prepd. These compds. are useful in the treatment of a disease state in which antagonism of the .alpha.V.beta.3 receptor is indicated, in particular osteoporosis (no data). They also inhibit angiogenesis, tumor growth, or tumor metastasis and are useful for the treatment of atherosclerosis, restenosis, or rheumatoid arthritis or as antineoplastic agents (no data). Thus, Me 3-(4-carboxy-1,3-oxazol-2-yl)-4-[4-[(tert-butyloxycarbonyl)oxy]phenyl]butanoate was condensed with morpholine in the presence of (i-Pr)2NEt, pyridine, and BPFFH at room temp. for 18 h, followed by treatment with 4 N HCl in dioxane at room temp. for 18 h to give, after silica gel chromatog., 88% Me (.+-.)-3-[4-[(morpholin-4-yl)carbonyl]-1,3-oxazol-2-yl]-4-(4-hydroxyphenyl)butanoate as a clear oil. The latter compd. was condensed with 6-(methylamino)-2-pyridylethanol using diisopropyl azodicarboxylate and triphenylphosphine in CH2Cl2 at room temp. for 18 h to give, after silica gel chromatog., Me (.+-.)-4-[4-[2-(6-methylaminopyridin-2-yl)-1-ethoxy]phenyl]-3-[4-[(morpholin-4-yl)carbonyl]-1,3-oxazol-2-yl]butanoate which was sapond. with a mixt. of 1.0 N LiOH and THF/H2O (1:1) and acidified to pH 6 using 10% HCl to give, after purifn. using reverse HPLC, (.+-.)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxyphenyl]-3-[4-(morpholin-4-yl)carbonyl]-1,3-oxazol-2-yl]butanoic acid (26% over 2 steps).

IT 329978-44-1P 329978-48-5P 329978-52-1P
329978-54-3P 329978-56-5P 329978-58-7P
329978-60-1P 329978-62-3P 329978-64-5P
329978-66-7P 329978-69-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [(pyridyl- or tetrahydronaphthyridinyl)ethoxy]phenyl]butanoic acid derivs. as vitronectin receptor antagonists and remedies for treating .alpha.V.beta.3 receptor-related diseases)


RN 329978-44-1 CAPLUS

CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-[4-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 329978-48-5 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[(methylphenylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 329978-52-1 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-(4-morpholinylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 329978-54-3 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[[methyl(2,2,2-trifluoroethyl)amino]carbonyl]-, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 329978-53-2


CMF C25 H27 F3 N4 O5




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 329978-56-5 CAPLUS
 CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[[methyl(2,2,2-trifluoroethyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 329978-58-7 CAPLUS
 CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 329978-60-1 CAPLUS
 CN 2-Thiazolepropanoic acid, 5-methyl-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 329978-62-3 CAPLUS
 CN Benzenebutanoic acid, .beta.-(3-fluorophenyl)-4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329978-64-5 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 329978-66-7 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329978-69-0 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 329978-50-9P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (intermediate; prepn. of [[(pyridyl- or tetrahydronaphthyridinyl)ethoxy]phenyl]butanoic acid derivs. as vitronectin receptor antagonists and remedies for treating .alpha.V.beta.3 receptor-related diseases)


RN 329978-50-9 CAPLUS
 CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-(4-morpholinylcarbonyl)-, trifluoroacetate (4:7) (9CI) (CA INDEX NAME)

CRN 329978-49-6
CMF C26 H30 N4 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 329978-43-0P 329978-45-2P 329978-46-3P
329978-49-6P 329978-53-2P 329978-57-6P
329978-59-8P 329978-61-2P 329978-63-4P
329978-65-6P 329978-67-8P 329978-70-3P
329978-71-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [[(pyridyl- or tetrahydronaphthylidene)ethoxy]phenyl]butanoic acid derivs. as vitronectin receptor antagonists and remedies for treating .alpha.V.beta.3 receptor-related diseases)


RN 329978-43-0 CAPLUS

CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329978-45-2 CAPLUS

CN 2-Oxazopropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[(methylphenylamino)carbonyl]- (9CI)
(CA INDEX NAME)




RN 329978-46-3 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[(methylphenylamino)carbonyl]-, trifluoroacetate (20:37) (9CI) (CA INDEX NAME)

CM 1

CRN 329978-45-2


CMF C29 H30 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 329978-49-6 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 329978-53-2 CAPLUS


CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[[methyl(2,2,2-trifluoroethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 329978-57-6 CAPLUS


CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

NAME)



RN 329978-59-8 CAPLUS


CN 2-Thiazolepropanoic acid, 5-methyl-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 329978-61-2 CAPLUS

CN Benzenebutanoic acid, .beta.-(3-fluorophenyl)-4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, hydrochloride (4:9), (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 9/4 HCl

RN 329978-63-4 CAPLUS


CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, hydrochloride (10:13) (9CI) (CA INDEX NAME)



● 13/10 HCl


RN 329978-65-6 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329978-67-8 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329978-70-3 CAPLUS
 CN Benzenebutanoic acid, .beta.-(3-fluorophenyl)-4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 329978-71-4 CAPLUS
 CN 3-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AN 1999:594939 CAPLUS
 DN 131:214194
 TI Preparation of pyridinyloxyphenylbutanoates and related compounds as
 vitronectin receptor antagonists.
 IN Miller, William H.; Gleason, John G.; Heerding, Dirk; Samanen, James M.;
 Uzinskas, Irene N.; Manley, Peter J.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

SN 10/023471 elected subject
 is [N]

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945927	A1	19990916	WO 1999-US5232	19990310
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9901884	A	19990910	ZA 1999-1884	19990309
	CA 2323208	AA	19990916	CA 1999-2323208	19990310
	AU 9929033	A1	19990927	AU 1999-29033	19990310
	EP 1061921	A1	20001227	EP 1999-909952	19990310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9908636	A	20020108	BR 1999-8636	19990310
	JP 2002506033	T2	20020226	JP 2000-535342	19990310
	NO 2000004503	A	20001010	NO 2000-4503	20000908
	US 2002147334	A1	20021010	US 2002-23471	20020226
PRAI	US 1998-77610P	P	19980310		
	US 1998-96063P	P	19980811		
	WO 1999-US5232	W	19990310		
	US 2000-623827	B1	20000908		
OS	MARPAT 131:214194				
GI					



AB Title compds. [I; R = XCHR₁CH₂CO₂H, CH₂NR_fCH₂CO₂H, CH:CR_fCH₂CO₂H; X, Y = CR'R', NR', O, S; A = H, halo, cyano, NO₂, CF₃, amino, acyl, aryl, aryl(alkyl), heterocyclyl(alkyl), etc.; R₁ = heterocyclyl(alkyl), aryl(alkyl), H, cyano, CH:CH₂, C.tplbond.CH, etc.; R₂ = Q₁, Q₂, etc.; R' = H, alkyl, aryl(alkyl), cycloalkyl(alkyl); R'' = H, acyl; R_b, R_c = H, alkyl, aryl(alkyl), heterocyclyl(alkyl), cycloalkyl(alkyl), halo, CF₃, NO₂, amino, etc.; W = (CHRG)aU(CHRG)b; U = null, CO, O, S, SO, SO₂, imino, CO₂, C.tplbond.C, arylene, heterocyclylene, etc.; R_f = H, alkyl,


aryl(alkyl); Rg = H, alkyl, heterocycl(alkyl), cycloalkyl(alkyl), aryl(alkyl); a, b = 0-2; m, n = 0, 1; Q1-Q3 = N, CRy; Ry = H, halo, cyano, NO2, CF3, (substituted) alkyl, etc.], were prepd. for treatment of inflammation, cancer, atherosclerosis, restenosis, and osteoporosis (no data). Thus, diisopropyl azodicarboxylate was added to a mixt. of Et 4-(4-hydroxyphenyl)-3-phenylbutanoate (prepn. given), 2-[(3-hydroxy-1-propyl)amino]pyridine N-oxide (prepn. given), and Ph3P in DMF at 0.degree. followed by 23 h at room temp. to give 68% Et 3-phenyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoate. This was refluxed with cyclohexene and Pd/C in Me2CHOH to give 77% Et 3-phenyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoate. The latter was stirred with LiOH in THF/H2O to give 74% 3-phenyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoic acid.

IT 243640-55-3P 243640-64-4P 243640-67-7P
 243640-69-9P 243640-71-3P 243640-72-4P
 243640-74-6P 243640-77-9P 243640-79-1P
 243640-81-5P 243640-83-7P 243640-85-9P
 243640-86-0P 243640-87-1P 243640-89-3P
 243640-90-6P 243640-91-7P 243640-92-8P
 243640-93-9P 243640-94-0P 243640-95-1P
 243642-56-0P 243642-59-3P 243642-62-8P
 243642-63-9P 243642-64-0P 243642-65-1P
 243642-66-2P 243642-67-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridinyloxyphenylbutanoates and related compds. as vitronectin receptor antagonists)


RN 243640-55-3 CAPLUS

CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-phenyl- (9CI) (CA INDEX NAME)




RN 243640-64-4 CAPLUS

CN 2-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243640-67-7 CAPLUS

CN 2-Thiophenepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-69-9 CAPLUS


CN Benzenebutanoic acid, .beta.- (4-bromophenyl) -4- [2- [6- (methylamino) -2- pyridinyl]ethoxy] - (9CI) (CA INDEX NAME)



RN 243640-71-3 CAPLUS


CN Benzenebutanoic acid, 4- [2- [6- (methylamino) -2- pyridinyl]ethoxy] - .beta.- phenyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 243640-72-4 CAPLUS

CN Benzenebutanoic acid, 4- [2- [6- (methylamino) -2- pyridinyl]ethoxy] - .beta.- [4- (1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-74-6 CAPLUS


CN 2-Oxazolepropanoic acid, .beta.- [[4- [2- [6- (methylamino) -2- pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-77-9 CAPLUS


CN 2-Thiazolepropanoic acid, .beta.- [[4- [2- [6- (methylamino) -2-

pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-79-1 CAPLUS


CN 2-Furanpropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-81-5 CAPLUS


CN Benzenebutanoic acid, .beta.-phenyl-4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 243640-83-7 CAPLUS


CN 1H-Imidazole-2-propanoic acid, 1-[(dimethylamino)sulfonyl]-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 243640-85-9 CAPLUS

CN 1H-Imidazole-2-propanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 243640-86-0 CAPLUS

CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 243640-87-1 CAPLUS


CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, (.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 243640-89-3 CAPLUS

CN Benzenebutanoic acid, .beta.-cyclopropyl-4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 243640-90-6 CAPLUS

CN 2-Benzothiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243640-91-7 CAPLUS
 CN 2-Benzothiazolepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 243640-92-8 CAPLUS
 CN 2-Thiazolepropanoic acid, 4-methyl-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243640-93-9 CAPLUS
 CN 2-Oxazolepropanoic acid, 4-carboxy-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243640-94-0 CAPLUS
 CN 2-Oxazolepropanoic acid, 4-(aminocarbonyl)-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243640-95-1 CAPLUS
 CN 2-Oxazolepropanoic acid, 4-[(dimethylamino)carbonyl]-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 243642-56-0 CAPLUS
 CN 2-Thiophenepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 243640-67-7
 CMF C22 H24 N2 O3 S



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 243642-59-3 CAPLUS
 CN Benzenebutanoic acid, .beta.-(4-bromophenyl)-4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-, hydrochloride (2:3) (9CI) (CA INDEX NAME)




● 3/2 HCl

RN 243642-62-8 CAPLUS
 CN 1H-Imidazole-2-propanoic acid, 1-[(dimethylamino)sulfonyl]-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 243642-63-9 CAPLUS
 CN 1H-Imidazole-2-propanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 243642-64-0 CAPLUS
 CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 243642-65-1 CAPLUS
 CN 2-Oxazolepropanoic acid, 4-carboxy-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1


CRN 243640-93-9
 CMF C22 H23 N3 O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 243642-66-2 CAPLUS

CN 2-Oxazolepropanoic acid, 4-(aminocarbonyl)-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 243640-94-0


CMF C22 H24 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 243642-67-3 CAPLUS

CN 2-Oxazolepropanoic acid, 4-[(dimethylaminocarbonyl)-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1

CRN 243640-95-1


CMF C24 H28 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 243641-58-9P 243641-59-0P 243641-78-3P
 243641-85-2P 243641-86-3P 243641-87-4P
 243641-92-1P 243642-02-6P 243642-07-1P
 243642-09-3P 243642-11-7P 243642-19-5P
 243642-21-9P 243642-23-1P 243642-25-3P
 243642-27-5P 243642-29-7P 243642-31-1P
 243642-33-3P 243642-35-5P 243642-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyridinylethoxyphenylbutanoates and related compds. as vitronectin receptor antagonists)


RN 243641-58-9 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-4-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 243641-59-0 CAPLUS

CN 2-Oxazolepropanoic acid, 4-carboxy-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, .alpha.-methyl ester (9CI) (CA INDEX NAME)




RN 243641-78-3 CAPLUS

CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 243641-85-2 CAPLUS

CN 2-Pyridinepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 243641-86-3 CAPLUS

CN 2-Oxazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 243641-87-4 CAPLUS

CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 243641-92-1 CAPLUS


CN 2-Thiophenepropanoic acid, .beta.-[[4-[2-[6-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-pyridinyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 243642-02-6 CAPLUS


CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-phenyl-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 243642-07-1 CAPLUS

CN Benzenebutanoic acid, .beta.-(4-bromophenyl)-4-[2-[6-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-pyridinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 243642-09-3 CAPLUS

CN Benzenebutanoic acid, .beta.-(4-bromophenyl)-4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 243642-11-7 CAPLUS


CN Benzenebutanoic acid, 4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-.beta.-[4-(1-methylethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 243642-19-5 CAPLUS


CN Benzenebutanoic acid, .beta.-phenyl-4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243642-21-9 CAPLUS


CN 1H-Imidazole-2-propanoic acid, 1-[(dimethylamino)sulfonyl]-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 243642-23-1 CAPLUS

CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 243642-25-3 CAPLUS


CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester, (.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243642-27-5 CAPLUS


CN 2-Benzothiazolepropanoic acid, .beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 243642-29-7 CAPLUS

CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 243642-31-1 CAPLUS


CN 2-Thiazolepropanoic acid, 4-methyl-.beta.-[[4-[2-[6-(methylamino)-2-

pyridinyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 243642-33-3 CAPLUS

CN 2-Oxazolepropanoic acid, 4-(aminocarbonyl)-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 243642-35-5 CAPLUS

CN 2-Oxazolepropanoic acid, 4-[(dimethylamino)carbonyl]-.beta.-[[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 243642-47-9 CAPLUS

CN Benzenebutanoic acid, .beta.-cyclopropyl-4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT